Does seasonal variation affect hallucinations in PD? A longitudinal study

Christopher G. Goetz, John Michael Li, Joanne Wuu, Sue Leurgans

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The objective of this study was to examine the chronobiology of visual hallucinations in Parkinson's disease (PD) patients to test whether hallucinations are more severe during darker months (winter) than summer months. We extracted longitudinal data on the UPDRS Thought Disorder (TD) score, taken as part of regular patient management on sequential visits through a 1-year cycle in hallucinating PD patients. To reduce the confounding effects of medication adjustments, analysis was restricted to patients with a baseline evaluation that did not involve a medication change. The primary outcome was the seasonal change in hallucination severity, defined as a change in TD score or neuroleptic use. Using Wilcoxon rank-sum tests, we compared the exacerbation of hallucination by season, focusing on winter (December through February) versus summer (June through August). A total of 51 hallucinating patients met entry criteria, and their longitudinal data were analyzed. There was no difference in hallucination severity with changing season; the level of wintertime exacerbation was no greater than summertime exacerbation (P = 0.42). Although hallucinations frequently develop in dimmed environments and evening hours, the darkness of wintertime does not exacerbate hallucinations in PD subjects on stable medications. Because we found no evidence of seasonal variations, we cannot recommend phototherapy or other strategies affecting chronobiological systems as research priorities to treat PD hallucinations.

Original languageEnglish
Pages (from-to)863-865
Number of pages3
JournalMovement Disorders
Volume21
Issue number6
DOIs
StatePublished - Jun 1 2006
Externally publishedYes

Fingerprint

Hallucinations
Parkinson Disease
Longitudinal Studies
Nonparametric Statistics
Social Adjustment
Phototherapy
Darkness
Antipsychotic Agents
Research

Keywords

  • Chronobiology
  • Hallucinations
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Does seasonal variation affect hallucinations in PD? A longitudinal study. / Goetz, Christopher G.; Li, John Michael; Wuu, Joanne; Leurgans, Sue.

In: Movement Disorders, Vol. 21, No. 6, 01.06.2006, p. 863-865.

Research output: Contribution to journalArticle

Goetz, Christopher G. ; Li, John Michael ; Wuu, Joanne ; Leurgans, Sue. / Does seasonal variation affect hallucinations in PD? A longitudinal study. In: Movement Disorders. 2006 ; Vol. 21, No. 6. pp. 863-865.
@article{9dcd3df03f37439f91a4eb066ebc8c46,
title = "Does seasonal variation affect hallucinations in PD? A longitudinal study",
abstract = "The objective of this study was to examine the chronobiology of visual hallucinations in Parkinson's disease (PD) patients to test whether hallucinations are more severe during darker months (winter) than summer months. We extracted longitudinal data on the UPDRS Thought Disorder (TD) score, taken as part of regular patient management on sequential visits through a 1-year cycle in hallucinating PD patients. To reduce the confounding effects of medication adjustments, analysis was restricted to patients with a baseline evaluation that did not involve a medication change. The primary outcome was the seasonal change in hallucination severity, defined as a change in TD score or neuroleptic use. Using Wilcoxon rank-sum tests, we compared the exacerbation of hallucination by season, focusing on winter (December through February) versus summer (June through August). A total of 51 hallucinating patients met entry criteria, and their longitudinal data were analyzed. There was no difference in hallucination severity with changing season; the level of wintertime exacerbation was no greater than summertime exacerbation (P = 0.42). Although hallucinations frequently develop in dimmed environments and evening hours, the darkness of wintertime does not exacerbate hallucinations in PD subjects on stable medications. Because we found no evidence of seasonal variations, we cannot recommend phototherapy or other strategies affecting chronobiological systems as research priorities to treat PD hallucinations.",
keywords = "Chronobiology, Hallucinations, Parkinson's disease",
author = "Goetz, {Christopher G.} and Li, {John Michael} and Joanne Wuu and Sue Leurgans",
year = "2006",
month = "6",
day = "1",
doi = "10.1002/mds.20840",
language = "English",
volume = "21",
pages = "863--865",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Does seasonal variation affect hallucinations in PD? A longitudinal study

AU - Goetz, Christopher G.

AU - Li, John Michael

AU - Wuu, Joanne

AU - Leurgans, Sue

PY - 2006/6/1

Y1 - 2006/6/1

N2 - The objective of this study was to examine the chronobiology of visual hallucinations in Parkinson's disease (PD) patients to test whether hallucinations are more severe during darker months (winter) than summer months. We extracted longitudinal data on the UPDRS Thought Disorder (TD) score, taken as part of regular patient management on sequential visits through a 1-year cycle in hallucinating PD patients. To reduce the confounding effects of medication adjustments, analysis was restricted to patients with a baseline evaluation that did not involve a medication change. The primary outcome was the seasonal change in hallucination severity, defined as a change in TD score or neuroleptic use. Using Wilcoxon rank-sum tests, we compared the exacerbation of hallucination by season, focusing on winter (December through February) versus summer (June through August). A total of 51 hallucinating patients met entry criteria, and their longitudinal data were analyzed. There was no difference in hallucination severity with changing season; the level of wintertime exacerbation was no greater than summertime exacerbation (P = 0.42). Although hallucinations frequently develop in dimmed environments and evening hours, the darkness of wintertime does not exacerbate hallucinations in PD subjects on stable medications. Because we found no evidence of seasonal variations, we cannot recommend phototherapy or other strategies affecting chronobiological systems as research priorities to treat PD hallucinations.

AB - The objective of this study was to examine the chronobiology of visual hallucinations in Parkinson's disease (PD) patients to test whether hallucinations are more severe during darker months (winter) than summer months. We extracted longitudinal data on the UPDRS Thought Disorder (TD) score, taken as part of regular patient management on sequential visits through a 1-year cycle in hallucinating PD patients. To reduce the confounding effects of medication adjustments, analysis was restricted to patients with a baseline evaluation that did not involve a medication change. The primary outcome was the seasonal change in hallucination severity, defined as a change in TD score or neuroleptic use. Using Wilcoxon rank-sum tests, we compared the exacerbation of hallucination by season, focusing on winter (December through February) versus summer (June through August). A total of 51 hallucinating patients met entry criteria, and their longitudinal data were analyzed. There was no difference in hallucination severity with changing season; the level of wintertime exacerbation was no greater than summertime exacerbation (P = 0.42). Although hallucinations frequently develop in dimmed environments and evening hours, the darkness of wintertime does not exacerbate hallucinations in PD subjects on stable medications. Because we found no evidence of seasonal variations, we cannot recommend phototherapy or other strategies affecting chronobiological systems as research priorities to treat PD hallucinations.

KW - Chronobiology

KW - Hallucinations

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=33745859393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745859393&partnerID=8YFLogxK

U2 - 10.1002/mds.20840

DO - 10.1002/mds.20840

M3 - Article

C2 - 16538649

AN - SCOPUS:33745859393

VL - 21

SP - 863

EP - 865

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 6

ER -